Where does Neupharma, Inc rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Neupharma, Inc ranks #8,261 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Neupharma, Inc hold?

Neupharma, Inc holds 39 US utility patents granted between 2016 and 2025, spanning 9 technology areas.

What is Neupharma, Inc's Innovation Score?

Neupharma, Inc has an Innovation Score of 40.7 out of 100 (top 35% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Neupharma, Inc's patent grant rate increasing or decreasing?

Neupharma, Inc's recent grant velocity is -48% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Neupharma, Inc's patents?

Neupharma, Inc's patents average 24.3 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Neupharma, Inc patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Neupharma, Inc

Q: What technology areas does Neupharma, Inc focus on?

Neupharma, Inc's top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 38 patents. Grants appear in 9 CPC subclasses total.

USPTO PatentsView assignee record - 39 granted patents across 9 technology areas, recorded in grant years 2016–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Neupharma ranks #8,261 of 49,997 tracked US assignees by granted-patent volume, with 39 patents across 9 technology areas.

#8,261
of 49,997 US assignees by volume: Top 35%
by Innovation Score (40.7/100): 24.3
avg claims per patent: -48%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R8261 · US Corporation #8,261 · 39 grants

GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-DENSE · TYPE-USCORP · VEL-DROP · BOOK-FULL

GRANTS-SMALL 39 grants
UPPER-Q #8,261/49,997
PHOTO-FINISH National University…
CPC-NARROW A61P · 9 areas
INNOV-PAR 40.7/100
CLAIMS-DENSE 24.3 claims/avg
TYPE-USCORP US Corporation
VEL-DROP -48% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: National University Corporation Nara Institute OF Science AND Technology (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Qualcomm Incorporated · highest

85
HS Marston Aerospace · near

41
Evonik Industries · near

41
Neupharma · this assignee

41
Unilin Bvba · near

41
Nippon Piston Ring · near

41
3D Lighting… · lowest

7

What this shows Neupharma's Innovation Score is 40.7/100 (top 35% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Where Neupharma's grants concentrate

Neupharma, Inc is a focused PatentsView assignee: 9 CPC subclasses with 97.4% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2017 (9 grants) versus a trough of 2 in 2021. By volume, Neupharma sits between National University Corporation Nara Institute OF Science AND Technology and NOVADELTA—COMÉRCIO E INDÚSTRIA DE CAFÉS, LDA.

Neupharma's three-year grant acceleration

Neupharma, Inc shows 5 grants in 2022–2024 against only 12 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

National Universi…

39
Ncku Research and…

39
NEC Europe

39
Netradyne

39
Newpark Mats & In…

39
Nippon Piston Ring

39
Nittoh

39
Novadelta—COMÉRCI…

39
Neupharma ◀

39

What this shows Neupharma holds 39 patents at rank #8,259, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Neupharma

By rank, the assignees closest to #8,259 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Neupharma's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Neupharma, neither rank-band nor same-CPC leaders (those blocks stay above).

Similar innovation score

Nearest assignees by Innovation Score (41 here).

Unilin Bvba 41 Evonik Industries AG 41 Nippon Piston Ring Co., Ltd. 41 HS Marston Aerospace Limited 41

Neupharma's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

41 Top 35% higher than 65% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2016–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.

View data table

Neupharma, Inc patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2016	7	17.9%
2017	9	23.1%
2018	5	12.8%
2019	4	10.3%
2020	6	15.4%
2021	2	5.1%
2022	3	7.7%
2024	2	5.1%
2025partial year	1	2.6%

Which technologies does Neupharma, Inc patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 38

C07D - Heterocyclic Compounds 31

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 31

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 13

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 12

C07C - Acyclic OR Carbocyclic Compounds 9

C07J - Steroids 8

A61J - Containers Specially Adapted FOR Medical OR Pharmaceutical PURPOSES; Devices OR Methods Specially Adapted FOR Bringing Pharmaceutical Products Into Particular Physical OR Administering FORMS; Devices FOR Administering Food OR Medicines ORALLY; Baby COMFORTERS; Devices FOR Receiving Spittle 2

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 1

Top 9 of 9 technology areas

Where it ranks

Overall rank by patents

#8,261

of 49,997 tracked assignees

Innovation Score

40.7 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Neupharma, Inc's patent record in context - here's where to go next.

Neupharma, Inc's lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 97.4% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #8,261 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Neupharma, Inc against National University Corporation Nara Institute OF Science AND Technology, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 40.7/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.